CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
bortezomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00262873
NCT00262873Phase 2Completed
CompareCT.gov

A Phase II Pilot Study of VELCADE in Patients With MDS

University of Rochester·interventional·Posted Dec 7, 2005·Updated May 9, 2016

In Brief

A Phase 2 clinical trial evaluating bortezomib for Myelodysplastic Syndromes. Completed, enrolled 8 participants across 1 site.

Detailed Summary

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with myelodysplastic syndromes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndromes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 7, 2005
Enrollment StartMay 1, 2005
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 20.6 years ago

Interventions

bortezomibdrug